Revised forecast
Fiscal year ending December 2026 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
While revenue from existing businesses can now be estimated regardless of regulatory developments, the timing of new drug launches and regulatory approvals for new medtech businesses, research and development expenses, upfront and strategic investments, and recognition of the gain on debt forgiveness associated with the acquisition of Cullgen remain uncertain, making it difficult to reasonably calculate profit items.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥27,158 million |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Previous-period results | Revenue of ¥26,840 million, operating loss of ¥3,471 million, loss before tax of ¥4,634 million, loss for the year of ¥7,150 million, loss for the year attributable to owners of the parent of ¥4,244 million, and basic earnings per share of -¥80.90 |
| Reason for the revision | While revenue from existing businesses can now be estimated regardless of regulatory developments, the timing of new drug launches and regulatory approvals for new medtech businesses, research and development expenses, upfront and strategic investments, and recognition of the gain on debt forgiveness associated with the acquisition of Cullgen remain uncertain, making it difficult to reasonably calculate profit items. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company can now estimate revenue from its existing businesses with reasonable certainty, regardless of regulatory developments. However, the timing of new drug launches and regulatory approvals for new medtech businesses, research and development expenses, upfront and strategic investments, and recognition of the gain on debt forgiveness associated with the acquisition of Cullgen remain uncertain, making it difficult to reasonably calculate profit.